Safety of Live Case Demonstrations in Patients Undergoing Percutaneous Coronary Intervention for Chronic Total Occlusion

详细信息    查看全文

• 作者：Tetsuro Shimura ; MD^a ; Masanori Yamamoto ; MD^a ; ^{yamamoto@heart-center.or.jp" class="auth_mail" title="E-mail the corresponding author} ; ^{masa-nori@nms.ac.jp" class="auth_mail" title="E-mail the corresponding author} ; Etsuo Tsuchikane ; MD^a ; ^{Tsuchikane@heart-center.or.jp" class="auth_mail" title="E-mail the corresponding author} ; Tomohiko Teramoto ; MD^a ; Masashi Kimura ; MD^a ; Hirotomo Satou ; MD^a ; Hitoshi Matsuo ; MD^b ; Yoshiaki Kawase ; MD^b ; Yoriyasu Suzuki ; MD^c ; Seiji Kano ; MD^c ; Maoto Habara ; MD^a ; Kenya Nasu ; MD^a ; Yoshihisa Kinoshita ; MD^a ; Mitsuyasu Terashima ; MD^a ; Tetsuo Matsubara ; MD^a ; Takahiko Suzuki ; MD^a
• 刊名：The American Journal of Cardiology
• 出版年：2016
• 出版时间：1 October 2016
• 年：2016
• 卷：118
• 期：7
• 页码：967-973
• 全文大小：505 K

文摘

The data regarding the risk and benefits associated with live demonstrations at interventional cardiology congresses are scarce and controversial. We aimed to assess the clinical safety of chronic total occlusion percutaneous coronary intervention (CTO-PCI) procedures during live demonstrations. From January 2008 to December 2013, 739 consecutive patients underwent CTO-PCI at our center, and 199 patients were scheduled to undergo live CTO-PCI demonstrations at cardiology congresses that were globally transmitted to international meetings. The baseline characteristics, procedural complications, and clinical outcomes were compared between the live demonstration group and nonlive demonstration group. The procedural success rates were similar in the live demonstration group than in the nonlive demonstration group (91.5% vs 86.7%, p = 0.076), although the CTO lesions were longer and more tortuous in the live demonstration group (p = 0.029, p = 0.022, respectively). No cases of 30-day mortality were noted in the live demonstration group (0% vs 0.7%, p = 0.28), and no significant differences in procedural complications, such as coronary dissection, coronary perforation, and cardiac tamponade, were observed between the groups (p = 0.53, p = 0.12, and p = 0.40, respectively). The survival rates were similar in the 2 groups at a median follow-up duration of 51.2 ± 28.9 months (log-rank test: p = 0.45). Compared with cases of unsuccessful CTO-PCI, the cases of successful CTO-PCI exhibited improved all-cause survival in both the live and nonlive demonstration groups (log-rank test: p = 0.045, p = 0.0056, respectively). In conclusion, we found that procedural and clinical outcomes of live demonstration CTO-PCI were not significantly different compared with cases undergoing routine CTO-PCI procedures.